UroGen Pharma publishes long-term Jelmyto follow-up study results

UroGen Pharma (URGN) highlighted results from a long-term follow-up study with Jelmyto for pyelocalyceal solution, which is FDA approved for the treatment of low-grade, upper tract urothelial cancer in adult patients. Among patients from the OLYMPUS trial who achieved a complete response after primary chemoablation with Jelmyto, the median duration of response was 47.8 months. The study results are published online in the Journal of Urology. Of the 71 patients enrolled in OLYMPUS, 41 achieved a complete response after treatment with Jelmyto and had a median duration of response of 47.8 months, with median follow-up of 28.1 months. The analysis has certain limitations, including its post-hoc nature and the inherent selection bias of the 20 patients enrolled in the long-term follow-up study. To further explore the potential of Jelmyto in treating patients with UTUC, investigators are currently enrolling participants in the Jelmyto uTRACT Registry to gather longitudinal real-world usage data. As of July 10, 19 sites have been activated with 191 patients enrolled.